TABLE 3

Adverse events and their management recorded during the treatment period

Complete cohortPirfenidoneNintedanib
Type of adverse events301416
 Photosensitivity3 (10)3 (21.4)0 (0)
 Diarrhoea7# (23.3)0 (0)9# (56.3)
 Liver toxicity0 (0)0 (0)0 (0)
 Bleeding0 (0)0 (0)0 (0)
 Gastrointestinal upset4 (13.3)1 (7.1)3 (18.8)
 Fatigue3 (10)1 (7.1)2 (12.5)
 Death5 (16.7)2 (14.3)3 (18.8)
Management of adverse events
 Symptomatic management3 (12)0 (0)5 (31.3)
 Dose reduction5 (20)1 (7.1)4# (25)
 Drug discontinuation5 (20)3 (21.4)2 (12.5)
 Switch to alternative antifibrotic4 (16)3 (21.4)1 (6.3)

Data are presented as n or n (%). #: one patient switched from pirfenidone to nintedanib experienced diarrhoea which was managed with dose reduction; : death occurred in one patient switched from pirfenidone to nintedanib and in one patient switched from nintedanib to pirfenidone.